Notice of Special Interest (NOSI): Strengthening the HIV Care Continuum

Notice Special Interest NOSI): Strengthening HIV Care Continuum Notice Number: NOT-MH-20-023 Key Dates Release Date: March 30, 2020 First Available Due Date: 07, 2020 Expiration Date: 08, 2023 Related Announcements PA-20-144, Innovations HIV Prevention, Testing, Adherence Retention Optimize HIV Prevention Care Continuum Outcomes R01 Clinical Trial Optional) PA-20-145, Innovations HIV Prevention, Testing, Adherence Retention Optimize HIV Prevention Care Continuum Outcomes R21 Clinical Trial Optional) PA-20-141, Formative Pilot Intervention Research Prevention Treatment HIV/AIDS R34 Clinical Trial Optional) PA-19-126, Mentored Research Scientist Development Award Parent K01 - Independent Clinical Trial Allowed PA-19-127, Mentored Research Scientist Development Award Parent K01 - Independent Clinical Trial Required) PA-19-116, Mentored Clinical Scientist Research Career Development Award Parent K08 Independent Clinical Trial Required) PA-19-117, Mentored Clinical Scientist Research Career Development Award Parent K08 Independent Clinical Trial Allowed) PA-19-118, Mentored Patient-Oriented Research Career Development Award Parent K23 Independent Clinical Trial Required) PA-19-119, Mentored Patient-Oriented Research Career Development Award Parent K23 – Independent Clinical Trial Allowed) PA-19-052, NIH Small Research Grant Program Parent R03 Clinical Trial Allowed) PA-19-129, NIH Pathway Independence Award Parent K99/R00 Independent Clinical Trial Required) PA-19-130, NIH Pathway Independence Award Parent K99/R00 - Independent Clinical Trial Allowed) PA-19-121, Midcareer Investigator Award Patient-Oriented Research Parent K24 Independent Clinical Trial Required) PA-19-122, Midcareer Investigator Award Patient-Oriented Research Parent K24 Independent Clinical Trial Allowed) PA-19-272, PHS 2019-02 Omnibus Solicitation the NIH, CDC, FDA Small Business Innovation Research Grant Applications Parent SBIR R43/R44] Clinical Trial Allowed) PA-19-273, PHS 2019-02 Omnibus Solicitation the NIH, CDC, FDA Small Business Innovation Research Grant Applications Parent SBIR R43/R44] Clinical Trial Required) PA-19-270, PHS 2019-02 Omnibus Solicitation the NIH Small Business Technology Transfer Grant Applications Parent STTR R41/R42] Clinical Trial Allowed PA-19-271, PHS 2019-02 Omnibus Solicitation the NIH Small Business Technology Transfer Grant Applications Parent STTR R41/R42] Clinical Trial Required PAR-19-051, Emerging Global Leader Award K43 Independent Clinical Trial Required) PAR-19-098, Emerging Global Leader Award K43 Independent Clinical Trial Allowed) PAR-17-485, NIMH Research Education Mentoring Program HIV/AIDS Researchers R25) PAR-18-714, Academic Research Enhancement Award Undergraduate-Focused Institutions R15 - Clinical Trial Allowed) PAR-19-133, Academic Research Enhancement Award Undergraduate-Focused Institutions R15 – Clinical Trial Required) PAR-19-134, Research Enhancement Award Program REAP) Health Professional Schools Graduate Schools R15 Clinical Trial Allowed) PAR-19-135, Research Enhancement Award Program REAP) Health Professional Schools Graduate Schools R15 Clinical Trial Required) PAR-19-283, Fogarty HIV Research Training Program Low-and Middle-Income Country Institutions D43 Clinical Trial Optional) PA-19-192, Ruth L. Kirschstein National Research Service Award NRSA) Individual Fellowship Students Institutions Without NIH-Funded Institutional Predoctoral Dual-Degree Training Programs Parent F30) PA-19-195, Ruth L. Kirschstein National Research Service Award NRSA) Individual Predoctoral Fellowship Parent F31) PA-19-196, Ruth L. Kirschstein National Research Service Award NRSA) Individual Predoctoral Fellowship Promote Diversity Health-Related Research Parent F31 Diversity) PA-19-188, Ruth L. Kirschstein National Research Service Award NRSA) Individual Postdoctoral Fellowship Parent F32) PA-18-403, Ruth L. Kirschstein National Research Service Award NRSA) Institutional Research Training Grant Parent T32) Issued National Institute Mental Health NIMH) Purpose Notice calls research understanding addressing gaps the HIV care continuum. the United States globally, ambitious goals been targeted HIV testing, adherence, retention care, viral suppression optimize HIV clinical outcomes preventive benefit. each step the HIV care continuum, have significant advances optimize likelihood viral suppression men, women, children living HIV. example, innovative approaches been developed increase rates HIV testing, such the of social networks, technology-based approaches, HIV self-test distribution, community mobilization, the implementation HIV testing access non-medical settings. adherence HIV medication regimens, significant investment advances been to develop implement objective measures HIV medication and range efficacious treatment adherence interventions. interventions increase adherence regimens been successfully implemented the US international settings. However, work needed, indicated below. Progress also made the development testing interventions designed sustain retention HIV care treatment over longer periods time. target the HIV care continuum gained increased attention import recent years, due the advances HIV treatment care have HIV disease can be considered chronic disease requires lifelong treatment. Relative the range efficacious approaches optimally target intervene increase rates HIV testing adherence HIV treatments, evidence base much smaller efficacious interventions prevent patients dropping HIV treatment promoting sustained retention HIV care. Similarly, is dearth proven interventions available locate re-engage persons dropped HIV care treatment who not currently receiving HIV treatment, well those without durable viral suppression. Current evidence indicates if 95% all persons living HIV know status, 95% those diagnosed receive antiretroviral treatment ART), 95% those treatment achieve sustained viral suppression, incident HIV infections decline, an end the HIV/AIDS pandemic achievable. some settings, is evidence with necessary resources, comprehensive strategy, effective approaches HIV testing, linkage care, adherence support, retention care, ldquo;95-95-95” targets feasible. e U.S. Ending HIV Epidemic PEPFAR 3.0 Strategy underscores importance doing ldquo;Right things, the Right Places” curb epidemic. Substantial challenges remain, however. Additional tools needed inform gaps strategies are unique specific populations, cities, regions, countries – enable scale-up services will achieve epidemic control. Studies encouraged examine multi-level factors can optimize care continuum success, including individual, contextual, structural. Applications appropriate this Notice include formative basic behavioral social science better understand step the care continuum and/or multiple steps the HIV care continuum, initial development pilot tests innovative approaches intervention, intervention efficacy trials implementation science. important aspect this be collaborations between scientific service entities communities. Research teams strongly encouraged have academic Department Health DOH) Ministry Health MOH) partnerships the research applications, order optimize match the research directions local needs, to optimize public health impact the research implementation findings. Notice also encourages researchers utilize developmental perspective addresses substantial changes occur across lifespan infancy through older adulthood) are associated HIV treatment challenges. Additionally, given complexity advancing HIV care research, multidisciplinary modeling approaches encouraged draw appropriately multiple disciplines reach solutions based novel understandings these complex problems. Areas Research Interest Areas programmatic interest include, are limited to: Studies identify interaction biological, behavioral, interpersonal, societal, environmental factors associated the risk transmitting HIV, vulnerability, disease progression resilience Studies identify gaps targets the HIV care continuum associated determinants inform intervention development Studies understand decrease differential effects biomedical HIV care strategies different populations; disparities include gender, age-related, racial/ethnic, sexual minority. Studies further elucidate individual-level risk using geospatial, neighborhood mapping other techniques determine target community-level risk. Studies develop, test, implement innovations HIV testing linkage care, could include advancements approaches technologies Studies develop, implement, evaluate approaches expedite earlier ART initiation persons diagnosed HIV Studies strategies promote ART engagement uptake among individuals substantial risk transmitting HIV Studies decision support tools help individuals, couples, clinicians informed choices HIV care options Studies develop test interventions improve linkage HIV care Studies develop test novel adherence interventions impact both behavioral adherence persistence, biological outcomes such viral suppression Studies understand address provider, clinic, systems-level factors may impact antiretroviral initiation, antiretroviral adherence, patient retention, the purpose informing provider training, clinic practice, healthcare policy Studies advance innovative approaches ART delivery Studies develop test interventions improve retention HIV care indicated Studies develop test interventions improve viral suppression including durable suppression) indicated Studies the impact varying models differentiated HIV care retention care Studies interventions prevent discontinuation HIV care, and/or address significant barriers retention care Studies develop test alternative strategies re-engage former patients HIV care Studies develop test targeted interventions designed reduce documented gender, age-related, racial/ethnic, sexual minority disparities HIV care continuum outcomes. Studies better understand overcome challenges faced mobile populations, such migrants, displaced people, individuals are homeless marginally housed, accessing benefitting HIV care services Studies develop test behavioral, provider, healthcare systems interventions facilitate uptake use ART regimens Studies utilize modeling simulation techniques systems science approaches e.g., network analyses systems dynamics approaches) identify most effective core elements interventions estimate test and where under conditions should targeted an individual, social group, family, community, health care other system achieve maximum benefit Studies develop use adaptive designs decision rules are based participant characteristics responses intervention order customize tailor intervention strategies is strongly recommended applicants review NIMH Division AIDS Research current Funding Opportunity Announcements available our website at https://www.nimh.nih.gov/about/organization/dar/aids-related-funding-op…), consult a Program Officer before application submission. NIMH published updated policies guidance investigators regarding human research protection clinical research data safety monitoring NOT-MH-15-025). application’s Protection Human Subjects section data safety monitoring plans should reflect policies guidance this notice. Plans the protection research subjects data safety monitoring be reviewed the NIMH consistency NIMH NIH policies federal regulations. Application Submission Information notice applies due dates or after 7, 2020 subsequent receipt dates through 7, 2023. Submit applications this initiative using of following funding opportunity announcements FOAs) any reissues these announcement through expiration date this notice. PA-20-144, Innovations HIV Prevention, Testing, Adherence Retention Optimize HIV Prevention Care Continuum Outcomes R01 Clinical Trial Optional) PA-20-145, Innovations HIV Prevention, Testing, Adherence Retention Optimize HIV Prevention Care Continuum Outcomes R21 Clinical Trial Optional) PA-20-141, Formative Pilot Intervention Research Prevention Treatment HIV/AIDS R34 Clinical Trial Optional) PA-19-126, Mentored Research Scientist Development Award Parent K01 - Independent Clinical Trial Allowed) PA-19-127, Mentored Research Scientist Development Award Parent K01 - Independent Clinical Trial Required) PA-19-116, Mentored Clinical Scientist Research Career Development Award Parent K08 Independent Clinical Trial Required) PA-19-117, Mentored Clinical Scientist Research Career Development Award Parent K08 Independent Clinical Trial Allowed) PA-19-118, Mentored Patient-Oriented Research Career Development Award Parent K23 Independent Clinical Trial Required) PA-19-119, Mentored Patient-Oriented Research Career Development Award Parent K23 – Independent Clinical Trial Allowed) PA-19-052, NIH Small Research Grant Program Parent R03 Clinical Trial Allowed) PA-19-129, NIH Pathway Independence Award Parent K99/R00 Independent Clinical Trial Required) PA-19-130, NIH Pathway Independence Award Parent K99/R00 - Independent Clinical Trial Allowed) PA-19-121, Midcareer Investigator Award Patient-Oriented Research Parent K24 Independent Clinical Trial Required) PA-19-122, Midcareer Investigator Award Patient-Oriented Research Parent K24 Independent Clinical Trial Allowed) PA-19-272, PHS 2019-02 Omnibus Solicitation the NIH, CDC, FDA Small Business Innovation Research Grant Applications Parent SBIR R43/R44] Clinical Trial Allowed) PA-19-273, PHS 2019-02 Omnibus Solicitation the NIH, CDC, FDA Small Business Innovation Research Grant Applications Parent SBIR R43/R44] Clinical Trial Required) PA-19-270, PHS 2019-02 Omnibus Solicitation the NIH Small Business Technology Transfer Grant Applications Parent STTR R41/R42] Clinical Trial Allowed PA-19-271, PHS 2019-02 Omnibus Solicitation the NIH Small Business Technology Transfer Grant Applications Parent STTR R41/R42] Clinical Trial Required PAR-19-051, Emerging Global Leader Award K43 Independent Clinical Trial Required) PAR-19-098, Emerging Global Leader Award K43 Independent Clinical Trial Allowed) PAR-17-485, NIMH Research Education Mentoring Program HIV/AIDS Researchers R25) PAR-18-714, Academic Research Enhancement Award Undergraduate-Focused Institutions R15 - Clinical Trial Allowed) PAR-19-133, Academic Research Enhancement Award Undergraduate-Focused Institutions R15 – Clinical Trial Required) PAR-19-134, Research Enhancement Award Program REAP) Health Professional Schools Graduate Schools R15 Clinical Trial Allowed) PAR-19-135, Research Enhancement Award Program REAP) Health Professional Schools Graduate Schools R15 Clinical Trial Required) PAR-19-283, Fogarty HIV Research Training Program Low-and Middle-Income Country Institutions D43 Clinical Trial Optional) PA-19-192, Ruth L. Kirschstein National Research Service Award NRSA) Individual Fellowship Students Institutions Without NIH-Funded Institutional Predoctoral Dual-Degree Training Programs Parent F30) PA-19-195, Ruth L. Kirschstein National Research Service Award NRSA) Individual Predoctoral Fellowship Parent F31) PA-19-196, Ruth L. Kirschstein National Research Service Award NRSA) Individual Predoctoral Fellowship Promote Diversity Health-Related Research Parent F31 Diversity) PA-19-188, Ruth L. Kirschstein National Research Service Award NRSA) Individual Postdoctoral Fellowship Parent F32) PA-18-403, Ruth L. Kirschstein National Research Service Award NRSA) Institutional Research Training Grant Parent T32) instructions the SF424 R&R) Application Guide and funding opportunity announcement used submission must followed, the following additions: funding consideration, applicants must include ldquo;NOT-MH-20-023” without quotation marks) the Agency Routing Identifier field box 4B) the SF424 R&R form. Applications without information box 4B not considered this initiative. Applications nonresponsive terms this NOSI be be considered the NOSI initiative. nbsp; Inquiries Please direct inquiries the contacts Section VII the listed funding opportunity announcements the following additions/substitutions: Scientific/Research Contact(s) Gregory Greenwood, PhD, MPH National Institute Mental Health NIMH) Telephone: 240-669-5532 Email: gregory.greenwood@nih.gov Peer Review Contact(s) Examine eRA Commons account review assignment contact information information appears weeks after submission due date). Financial/Grants Management Contact(s) Rita Sisco National Institute Mental Health NIMH) Telephone: 301-443-2805 Email: rita.sico@mail.gov nbsp; nbsp;